|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.505 EUR | +7.13% |
|
+5.92% | +105.12% |
| 07-09 | THX Pharma secures its financial roadmap |  |
| 06-23 | THX Pharma appoints Sophie Jacq Lapointe to its board of directors | |
| Market Cap | 58.91M 67.78M 55M 50.49M 95.2M 6.46B 96.86M 649M 254M 3.22B 255M 249M 10.63B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 35.21M 40.51M 32.87M 30.18M 56.9M 3.86B 57.9M 388M 152M 1.93B 152M 149M 6.35B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
91.97% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 week | +5.92% | ||
| 1 month | +17.46% | ||
| 3 months | +26.09% | ||
| 6 months | +74.48% | ||
| Current year | +105.12% |
| 1 week | 3.92 |  | 4.52 |
| 1 month | 3.46 | | 4.52 |
| 3 years | 0.3 | | 4.52 |
| 5 years | 0.3 | | 8.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2022-12-31 | |
Christine Placet
DFI | Director of Finance/CFO | - | 2024-03-31 |
Marie Sebille
CTO | Chief Tech/Sci/R&D Officer | - | 2021-10-18 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 2024-03-30 | |
| Chairman | - | 2024-03-30 | |
Julien Veys
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.13% | +5.92% | +64.41% | +252.70% | 67.78M | |
| +0.05% | +3.08% | +38.17% | +66.77% | 56.7B | |
| +0.39% | -6.11% | +23.35% | +61.93% | 51.97B | |
| +1.84% | +1.27% | -14.06% | -13.50% | 23.33B | |
| -0.15% | -6.00% | -9.42% | +344.47% | 21.34B | |
| +0.99% | -2.20% | +31.97% | -26.27% | 17.44B | |
| +9.91% | -2.51% | +188.84% | +326.19% | 14.77B | |
| +3.83% | -1.34% | +47.77% | +165.22% | 13.84B | |
| +1.61% | +0.56% | +439.92% | +166.12% | 12.12B | |
| +3.14% | -12.56% | +59.51% | +149.39% | 11.14B | |
| Average | +2.40% | -2.33% | +87.05% | +149.30% | 24.74B | |
| Weighted average by Cap. | +1.49% | -1.95% | +57.72% | +109.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | 11.9M 13.69M 11.11M 10.2M 19.23M 1.31B 19.57M 131M 51.31M 651M 51.43M 50.29M 2.15B | 4.3M 4.95M 4.01M 3.69M 6.95M 472M 7.07M 47.34M 18.54M 235M 18.58M 18.17M 776M |
| Net Debt | -23.7M -27.27M -22.13M -20.31M -38.3M -2.6B -38.97M -261M -102M -1.3B -102M -100M -4.28B | -27.4M -31.53M -25.58M -23.48M -44.28M -3.01B -45.05M -302M -118M -1.5B -118M -116M -4.94B |
Employees
-
Calendar
| Date | Price | Change |
|---|---|---|
| 26-08-04 | €4.505 | +7.13% |
| 26-08-03 | €4.205 | 0.00% |
| 26-07-31 | €4.205 | +2.56% |
| 26-07-30 | €4.100 | +2.37% |
| 26-07-29 | €4.005 | +1.26% |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.270EUR
Average target price
5.800EUR
Spread / Average Target
+35.83%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ALTHX Stock
- 3VG Stock
Select your edition
All financial news and data tailored to specific country editions
